These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25670523)

  • 1. Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib.
    Shi JG; Fraczkiewicz G; Williams WV; Yeleswaram S
    Clin Pharmacol Ther; 2015 Feb; 97(2):177-85. PubMed ID: 25670523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
    de Zwart L; Snoeys J; De Jong J; Sukbuntherng J; Mannaert E; Monshouwer M
    Clin Pharmacol Ther; 2016 Nov; 100(5):548-557. PubMed ID: 27367453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
    Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S
    J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
    Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
    J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study.
    Callegari E; Tse S; Doran AC; Goosen TC; Shaik N
    J Clin Pharmacol; 2024 Jan; 64(1):80-93. PubMed ID: 37731282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
    Huth F; Gardin A; Umehara K; He H
    Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
    Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
    Xu H; O'Gorman M; Tan W; Brega N; Bello A
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
    Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
    Freise KJ; Shebley M; Salem AH
    J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
    Ji T; Chen X; Yeleswaram S
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
    Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
    Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
    Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.